Preclinical studies have demonstrated the effectiveness of THZ1 to prevent cell proliferation and induce apoptosis in a variety of cancer types, such as high grade gliomas [93], T-cell acute lymphoblastic leukemia (T-ALL) [92], MYCN-dependent neuroblastoma [94], small-cell lung cancer [95], triple negative breast cancer [96,97], peripheral T-cell lymphomas [98], and esophageal squamous cell carcinoma [99]. This evidence concerns the gene MYCN and neuroblastoma.